Client NewsRoquefort Therapeutics plc: Presentation of Midkine Antibody Program Update at the Festival of Biologics Conference
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, is pleased to announce that its Midkine antibody program update will be presented on 3 November 2022 at the Festival of Biologics conference in Basel, Switzerland. The ROQA1 (CAB 102) and ROQA2 (CAB101) programs have demonstrated efficacy in validated in vivo models of breast cancer and osteosarcoma resulting in a significantly reduced metastatic index (P<0.05), safety in rodent and non-human primates toxicology studies, and scalable production of CAB102.
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.